Semaglutide

FDA Approved

Semaglutide (GLP-1 Receptor Agonist)

Also known as: Ozempic, Wegovy, Rybelsus

Moderate Risk

Fat Loss

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management. The most commercially successful peptide drug. ~12% of US adults have used GLP-1 RAs.

Benefits

Significant sustained weight loss (13-15% body weight)

Improved blood sugar control

Reduced cardiovascular risk

Appetite suppression and reduced cravings

Improved insulin sensitivity

Oral formulation available (25mg pill, Jan 2026)

Side Effects & Risks

Nausea (common initially)moderate

Vomiting and diarrheamoderate

Constipationmild

Potential muscle mass loss with fatmoderate

Rare: pancreatitis riskserious

Rare: thyroid C-cell tumor concernserious

Dosing Information

Typical Dose

0.25mg weekly escalating to 2.4mg weekly

Administration

Weekly subcutaneous injection or daily oral tablet

Cycle Length

Ongoing under physician supervision

Notes

Dose escalation over 16-20 weeks to minimize GI side effects.

Legal Status

FDA Status

FDA-APPROVED (Ozempic, Wegovy, Rybelsus)

Availability

Prescription at standard pharmacies

WADA Status

Not currently banned

Evidence

Evidence LevelVery High

Extensive Phase III clinical trials. WHO global guideline on GLP-1s for obesity (Dec 2025). Wegovy approved for MASH (Aug 2025).

Where to Buy

Available from verified suppliers

MetaVitality Labs Verified4.7

View Supplier

Semaglutide Research Vial

LyophilizedPurity: 98%+

COA Available Third-Party TestedIn Stock

NovaCompound Rx Verified4.9

View Supplier

Compounded Semaglutide Injection

Pre-MixedPurity: 99%+

COA Available Third-Party Tested Requires PrescriptionIn Stock